There are no effective antiviral drugs for novel coronavirus pneumonia, and hopes may be pinned on the successful introduction of a vaccine. A number of research institutions are now working intensively on vaccine development, and it may be necessary to develop a vaccine for the new coronavirus pneumonia through the five common vaccine development strategies. Some of the vaccines have made breakthroughs and are expected to enter clinical trials in April, and may be used directly on humans in some emergencies under guaranteed safety conditions. However, the actual launching of the vaccine must be after verifying its safety and efficacy before it can be formally launched on the market. Therefore, if all goes well, the vaccine may be available in late 2020 or early 2021. However, the clinical trial will take a long time, such as starting in April, first giving the vaccine to a portion of the population, and then observing whether there is any difference between the vaccinated and unvaccinated populations in terms of infection rates. Therefore, the vaccine needs to prove its effectiveness through practical tests, and it may take until the end of the year at the earliest to actually use it. Source: Dr. Yurai